Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

61.18 +9.23 (+17.77%)
Streaming Delayed Price Updated: 10:38 AM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
News headline image
Stifel Upgrades This Pharma Stock On Prospective FDA Approval For Dwarfism Drug ↗
Stifel 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021 ↗
Upgrades According to Benchmark, the prior rating for TopBuild Corp (NYSE: 
Via Benzinga
News headline image
Price To Earnings Ratio Insights For Biomarin Pharmaceutical ↗
In the current market session, Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) is trading at $80.65, after a 5.06% drop. However, over the past month, the stock spiked by... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers Pliant Therapeutics (NASDAQ:PLRX) shares rose 25.62% to $24.27 during Tuesday's pre-market session. The market value of their outstanding shares is at $872.2... 
Via Benzinga
News headline image
FDA Slaps Clinical Hold on BioMarin's Gene Therapy For Genetic Metabolism Disorder ↗
​​​​​​BioMarin Pharmaceutical Inc (NASDAQ: BMRN) faces another setback in its gene therapy development program after the FDA placed the phenylketonuria (PKU) gene... 
Via Benzinga
News headline image
Drug For Short-Limbed Dwarfism From Biomarin Wins European Approval ↗
The European Commission (EC) has approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Voxzogo (vosoritide) once-daily injection to treat achondroplasia. The... 
Via Benzinga
News headline image
Get Ready for a Potential Double in This Biopharmaceutical Stock in the Next 6 to 12 Months ↗
All it will take is an FDA approval and a partial repeat of history. 
Via The Motley Fool
News headline image
BioMarin Bounces Back With Solid Q2 Earnings, Nudges Up 2021 Guidance ↗
BioMarin Pharmaceutical Inc reported a 17% Y/Y increase in revenue to $501.7 million in Q2, beating the consensus of $448.8 million, attributable to Vimizim, Naglazyme, and Palynziq product revenues,... 
Via Talk Markets
News headline image
BioMarin Bounces Back With Solid Q2 Earnings, Nudges Up 2021 Guidance ↗
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) reported a 17% Y/Y increase in revenue to $501.7 million in Q2, beating the consensus of $448.8 million, attributable to... 
Via Benzinga
News headline image
BioMarin Pharmaceutical inc (BMRN) Q2 2021 Earnings Call Transcript ↗
BMRN earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Biomarin Pharmaceutical: Q2 Earnings Insights ↗
Shares of Biomarin Pharmaceutical (NASDAQ:BMRN) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 143.75% over the... 
Via Benzinga
News headline image
BioMarin Shares 5-Year Data From Open-Label Trial Of Hemophilia Gene Therapy ↗
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has announced new data from open-label Phase 1/2 trial of valoctocogene roxaparvovec, an investigational gene therapy... 
Via Benzinga
News headline image
BioMarin Expects EMA's CHMP Opinion In 1H 2022 For Its Hemophilia A Gene Therapy, FDA Resubmission In 2Q'22 ↗
The European Medicines Agency (EMA) has validated BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) marketing application seeking approval for hemophilia A gene... 
Via Benzinga
News headline image
EMA's Advisory Committee Backs Approval Of BioMarin's Dwarfism Candidate ↗
European Medical Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of BioMarin... 
Via Benzinga
News headline image
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More ↗
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
News headline image
EMA Grants BioMarin's Request For Speedy Review of Hemophilia A Gene Therapy ↗
The European Medicines Agency (EMA) has granted its request for accelerated assessment review to BioMarin Pharmaceutical Inc’s (NASDAQ: BMRN)... 
Via Benzinga
News headline image
Five-Year Data Of BioMarin's Hemophilia Gene Therapy Shows Sustained Benefit ↗
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has announced an update to its previously reported results from Phase 1/2 study of valoctocogene roxaparvovec, an... 
Via Benzinga
News headline image
Biomarin Pharmaceutical Inc (BMRN) Q1 2021 Earnings Call Transcript ↗
BMRN earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Biomarin Pharmaceutical: Q1 Earnings Insights ↗
Shares of Biomarin Pharmaceutical (NASDAQ:BMRN) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 79.55... 
Via Benzinga
News headline image
Preview: Biomarin Pharmaceutical's Earnings ↗
Biomarin Pharmaceutical (NASDAQ:BMRN) releases its next round of earnings this Thursday, April 29. Here is Benzinga's essential guide to Biomarin Pharmaceutical's Q1 earnings... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:... 
Via Benzinga
News headline image
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx ↗
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:... 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.